Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Fuji
Healthtrust
US Army
Medtronic
Cerilliant
US Department of Justice
Federal Trade Commission
Julphar
Citi

Generated: February 23, 2018

DrugPatentWatch Database Preview

VANTAS Drug Profile

« Back to Dashboard

When do Vantas patents expire, and when can generic versions of Vantas launch?

Vantas is a drug marketed by Endo Pharm and is included in one NDA.

The generic ingredient in VANTAS is histrelin acetate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the histrelin acetate profile page.

US Patents and Regulatory Information for VANTAS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharm VANTAS histrelin acetate IMPLANT;SUBCUTANEOUS 021732-001 Oct 12, 2004 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for VANTAS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharm VANTAS histrelin acetate IMPLANT;SUBCUTANEOUS 021732-001 Oct 12, 2004 ➤ Sign Up ➤ Sign Up
Endo Pharm VANTAS histrelin acetate IMPLANT;SUBCUTANEOUS 021732-001 Oct 12, 2004 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
Daiichi Sankyo
Julphar
Teva
Mallinckrodt
Cerilliant
Cantor Fitzgerald
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot